A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Carbon (Primary) ; Charcoal (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Sponsors Daewon Pharmaceutical
- 20 Jan 2021 New trial record
- 01 Jan 2021 Primary endpoint (Preference of formulation) has been met. as per results published in the Yonsei Medical Journal
- 01 Jan 2021 Results published in the Yonsei Medical Journal